Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $89.80 million. The enterprise value is -$9.69 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ORMP has 41.00 million shares outstanding. The number of shares has decreased by -0.21% in one year.
| Current Share Class | 41.00M |
| Shares Outstanding | 41.00M |
| Shares Change (YoY) | -0.21% |
| Shares Change (QoQ) | +3.35% |
| Owned by Insiders (%) | 12.89% |
| Owned by Institutions (%) | 10.68% |
| Float | 32.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 45.24 |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 26.81 |
| Quick Ratio | 26.69 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.69% and return on invested capital (ROIC) is -5.16%.
| Return on Equity (ROE) | -14.69% |
| Return on Assets (ROA) | -4.94% |
| Return on Invested Capital (ROIC) | -5.16% |
| Return on Capital Employed (ROCE) | -8.65% |
| Revenue Per Employee | $500,000 |
| Profits Per Employee | -$6.04M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $2.01 million in taxes.
| Income Tax | 2.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.13% in the last 52 weeks. The beta is 1.19, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -5.13% |
| 50-Day Moving Average | 2.36 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 39.47 |
| Average Volume (20 Days) | 135,028 |
Short Selling Information
The latest short interest is 208,680, so 0.51% of the outstanding shares have been sold short.
| Short Interest | 208,680 |
| Short Previous Month | 280,292 |
| Short % of Shares Out | 0.51% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 1.74 |
Income Statement
In the last 12 months, ORMP had revenue of $2.00 million and -$24.16 million in losses. Loss per share was -$0.60.
| Revenue | 2.00M |
| Gross Profit | 13,000 |
| Operating Income | -13.67M |
| Pretax Income | -22.22M |
| Net Income | -24.16M |
| EBITDA | -13.53M |
| EBIT | -13.67M |
| Loss Per Share | -$0.60 |
Full Income StatementBalance Sheet
The company has $97.94 million in cash and $912,000 in debt, giving a net cash position of $97.03 million or $2.37 per share.
| Cash & Cash Equivalents | 97.94M |
| Total Debt | 912,000 |
| Net Cash | 97.03M |
| Net Cash Per Share | $2.37 |
| Equity (Book Value) | 153.58M |
| Book Value Per Share | 3.78 |
| Working Capital | 95.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.07 million and capital expenditures -$23,000, giving a free cash flow of -$16.09 million.
| Operating Cash Flow | -16.07M |
| Capital Expenditures | -23,000 |
| Free Cash Flow | -16.09M |
| FCF Per Share | -$0.39 |
Full Cash Flow StatementMargins
| Gross Margin | 0.65% |
| Operating Margin | -683.65% |
| Pretax Margin | -1,110.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.21% |
| Shareholder Yield | 0.21% |
| Earnings Yield | -27.67% |
| FCF Yield | -18.42% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 5.98 and a Piotroski F-Score of 1.
| Altman Z-Score | 5.98 |
| Piotroski F-Score | 1 |
